779 reports of this reaction
2.1% of all RIFAXIMIN reports
#8 most reported adverse reaction
FATIGUE is the #8 most commonly reported adverse reaction for RIFAXIMIN, manufactured by Salix Pharmaceuticals, Inc.. There are 779 FDA adverse event reports linking RIFAXIMIN to FATIGUE. This represents approximately 2.1% of all 37,072 adverse event reports for this drug.
Patients taking RIFAXIMIN who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for RIFAXIMIN, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for RIFAXIMIN:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 779 FDA reports for RIFAXIMIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 2.1% of all adverse event reports for RIFAXIMIN, making it a notable side effect.
If you experience fatigue while taking RIFAXIMIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.